Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Februar 2025 08:30 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.
05. Februar 2025 08:30 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.
10. Dezember 2024 08:00 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
09. Dezember 2024 08:00 ET | Quelle: Myriad Genetics, Inc.

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.